Artificial Intelligence
Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain
<!– Name:DistributionId Value:8736375 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:d450ecdf-f8de-44dd-ae95-b7892935e4aa –>
New York, USA, Jan. 30, 2023 (GLOBE NEWSWIRE) — Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain
The prevalence of thrombocytopenia has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Thrombocytopenia and the growing research and development activities to develop novel therapies to treat Thrombocytopenia to drive the market. The companies developing the potential therapies in the last stage of development include argenx, HUTCHMED, Takeda, and several others.
DelveInsight’s ‘Thrombocytopenia Pipeline Insight – 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline thrombocytopenia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the thrombocytopenia pipeline domain.
Key Takeaways from the Thrombocytopenia Pipeline Report
- DelveInsight’s thrombocytopenia pipeline report depicts a robust space with 27+ active players working to develop 30+ pipeline therapies for thrombocytopenia treatment.
- Key thrombocytopenia companies such as Takeda, argenx, Keros Therapeutics, Sanofi, Veralox Therapeutics, Novartis Pharmaceuticals, Pfizer, HUTCHMED, Principia Biopharma, Genosco, UCB, Qilu Pharmaceutical, Jiangsu HengRui Medicine Co., Ltd., InnoCare Pharma, eXIthera Pharmaceuticals, Harbour BioMed (Guangzhou) Co. Ltd., CTI BioPharma, AO GENERIUM, Chugai Pharmaceutical, Takeda, PhytoHealth Corporation, Inmunova S.A., Biotest Pharmaceuticals, COUR Pharmaceuticals, HanAll Biopharma, and others are evaluating new drugs for thrombocytopenia to improve the treatment landscape.
- Promising thrombocytopenia pipeline therapies in various stages of development include Mezagitamab, Efgartigimod alfa, KER 050, Rilzabrutinib, VLX 1005, Iptacopan, PF 06755347, Sovleplenib, PF 06835375, Cevidoplenib, Rozanolixizumab, QL0911, Hetrombopag, Ianalumab, Orelabrutinib, EP-7041, HBM9161, PACIFICA, GNR-069, Crovalimab, TAK 755, PHN013, INM004, BT-595, CNP-105, HL161, and others.
- In January 2023, Takeda announced that the totality of evidence from a pre-planned interim analysis of a pivotal Phase III study supports the efficacy and safety of TAK-755 as enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP).The interim results showed that TAK-755 reduced the incidence of thrombocytopenia events by 60% (95% Confidence Interval, 30%-70%), an important marker of disease activity in cTTP, as compared to SoC. The proportion of subjects experiencing adverse events determined to be related to the treatment was substantially lower among subjects during treatment with TAK-755 (8.9%) compared to that while receiving SoC therapy (47.7%).
- In January 2023, HUTCHMED (China) Limited (“HUTCHMED”) announced that it had completed patient enrollment of ESLIM-01, a pivotal Phase III clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) in China. The last patient was enrolled on December 31, 2022.The ESLIM-01 study, initiated in October 2021, is a randomized, double-blinded, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of sovleplenib in treating adult patients with ITP. The primary endpoint of the study is the durable response rate. Secondary and exploratory endpoints include overall response rate (ORR), the incidence of treatment-emergent adverse events, and patient quality of life improvement. A total of 188 patients were enrolled.
- In April 2022, Biotest AG announced that the marketing authorisation application for the Biotest development product IgG Next Generation in the so-called decentralized procedure (DCP) was submitted in Germany and Austria by 31 March 2022. IgG Next Generation is the first product to be produced in Biotest’s new manufacturing facility Biotest Next Level (BNL).The marketing authorization application covers the biochemical-pharmaceutical-technical part, as well as the preclinical and clinical studies in the indications Primary Immunodeficiency Diseases (PID) and chronic Primary Immune Thrombocytopenia (ITP).
- In April 2022, Positive results from the Phase I/II dose-finding study evaluating the safety, pharmacokinetics, and clinical activity of rilzabrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor, in adults with heavily pre-treated immune thrombocytopenia (ITP) were published in the New England Journal of Medicine. Results demonstrated treatment with rilzabrutinib led to a rapid and durable increase in platelet count and supported an acceptable safety profile. Sanofi is investigating the safety and efficacy of twice daily rilzabrutinib (400 mg) for adults and adolescents with chronic ITP in the ongoing Phase 3 clinical study LUNA 3, initiated in April 2021.
- In May 2022, argenx SE announced positive data from the Phase III ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary ITP. ADVANCE met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo. ADVANCE is the first Phase 3 clinical trial of a neonatal Fc receptor (FcRn) blocker in ITP.
- In January 2022, HUTCHMED (China) Limited announced that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to HMPL-523, a novel, investigational spleen tyrosine kinase (“Syk”) inhibitor, for the treatment of chronic adult primary immune thrombocytopenia (“ITP”) patients who have received at least one prior therapy.
Request a sample and discover the recent advances in thrombocytopenia treatment drugs @ Thrombocytopenia Pipeline Report
The thrombocytopenia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage thrombocytopenia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the thrombocytopenia clinical trial landscape.
Thrombocytopenia Overview
Thrombocytopenia is the medical term for a platelet count that is less than 150000/microliter (for adults), the lower limit of normal. The hazards of thrombocytopenia range from no danger at all to bleeding risks and thrombosis. Platelets are blood cells that aid in blood clotting and wound healing. Uncertainty exists regarding the relationship between bleeding risk and thrombocytopenia severity. Platelet counts below 10,000/microliter can cause spontaneous bleeding, and numbers below 50,000/microL can cause surgical bleeding. Heparin-induced thrombocytopenia (HIT), antiphospholipid antibody syndrome (APS), disseminated intravascular coagulation (DIC), thrombotic microangiopathy (TMA), and paroxysmal nocturnal hemoglobinuria are a few situations where thrombocytopenia is linked to a risk of thrombosis (PNH). According to a prospective study, patients with mild thrombocytopenia (100000 to 150000/microliter) have a 10-year likelihood of acquiring autoimmune diseases, according to a prospective study.
Find out more about thrombocytopenia treatment drugs @ Drugs for Thrombocytopenia Treatment
A snapshot of the Thrombocytopenia Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Efgartigimod alfa | argenx | Phase III | Neonatal Fc receptor antagonists | Intravenous |
| Sovleplenib | HUTCHMED | Phase III | Syk kinase inhibitors | Oral |
| Cevidoplenib | Genosco | Phase II | Syk kinase inhibitors | Oral |
| Mezagitamab | Takeda | Phase II | Antibody-dependent cell cytotoxicity; T lymphocyte stimulants | Subcutaneous |
| KER 050 | Keros Therapeutics | Phase II | Erythropoiesis stimulants; Transforming growth factor beta inhibitors | Subcutaneous |
| VLX 1005 | Veralox Therapeutics | Phase I | 12-lipoxygenase inhibitors; Platelet aggregation inhibitors | Intravenous |
| PF 06755347 | Pfizer | Phase I | Immunomodulators | Intravenous |
Learn more about the emerging thrombocytopenia pipeline therapies @ Thrombocytopenia Clinical Trials
Thrombocytopenia Therapeutics Assessment
The thrombocytopenia pipeline report proffers an integral view of thrombocytopenia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Thrombocytopenia Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous
- Therapeutics Assessment By Molecule Type: Small molecule, Cell Therapy, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Neonatal Fc receptor antagonists, Syk kinase inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Erythropoiesis stimulants, Transforming growth factor beta inhibitors, 12-lipoxygenase inhibitors, Platelet aggregation inhibitors, Immunomodulators
- Key Thrombocytopenia Companies: Takeda, argenx, Keros Therapeutics, Sanofi, Veralox Therapeutics, Novartis Pharmaceuticals, Pfizer, HUTCHMED, Principia Biopharma, Genosco, UCB, Qilu Pharmaceutical, Jiangsu HengRui Medicine Co., Ltd., InnoCare Pharma, eXIthera Pharmaceuticals, Harbour BioMed (Guangzhou) Co. Ltd., CTI BioPharma, AO GENERIUM, Chugai Pharmaceutical, Takeda, PhytoHealth Corporation, Inmunova S.A., Biotest Pharmaceuticals, COUR Pharmaceuticals, HanAll Biopharma and others.
- Key Thrombocytopenia Pipeline Therapies: Mezagitamab, Efgartigimod alfa, KER 050, Rilzabrutinib, VLX 1005, Iptacopan, PF 06755347, Sovleplenib, PF 06835375, Cevidoplenib, Rozanolixizumab, QL0911, Hetrombopag, Ianalumab, Orelabrutinib, EP-7041, HBM9161, PACIFICA, GNR-069, Crovalimab, TAK 755, PHN013, INM004, BT-595, CNP-105, HL161, and others.
Dive deep into rich insights for new drugs for thrombocytopenia treatment; visit @ Thrombocytopenia Drugs
Table of Contents
| 1. | Thrombocytopenia Pipeline Report Introduction |
| 2. | Thrombocytopenia Pipeline Report Executive Summary |
| 3. | Thrombocytopenia Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Thrombocytopenia Clinical Trial Therapeutics |
| 6. | Thrombocytopenia Pipeline: Late Stage Products (Pre-registration) |
| 7. | Thrombocytopenia Pipeline: Late Stage Products (Phase III) |
| 7.1. | Efgartigimod alfa: argenx |
| 8. | Thrombocytopenia Pipeline: Mid Stage Products (Phase II) |
| 8.1. | Cevidoplenib: Genosco |
| 9. | Thrombocytopenia Pipeline: Early Stage Products (Phase I) |
| 9.1. | VLX 1005: Veralox Therapeutics |
| 10. | Thrombocytopenia Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Thrombocytopenia Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Thrombocytopenia Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the thrombocytopenia pipeline therapeutics, reach out @ Thrombocytopenia Medications
Related Reports
Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thrombocytopenia companies, including Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, among others.
Immune Thrombocytopenia Market
Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key immune thrombocytopenia companies, including Takeda, Biotest, GC Pharma, UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, among others.
Immune Thrombocytopenia Pipeline
Immune Thrombocytopenia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key immune thrombocytopenia companies, including Takeda, Biotest, GC Pharma, UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, among others.
Immune Thrombocytopenia Epidemiology Forecast
Immune Thrombocytopenia Epidemiology Forecast – 2033 report delivers an in-depth understanding of the disease, historical and forecasted immune thrombocytopenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Helicobacter pylori Infection Market
Helicobacter pylori Infection Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Helicobacter pylori infection companies, including Phathom Pharmaceuticals, Redhill Biopharma, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvisé Pharmaceuticals, among others.
Helicobacter pylori Infection Pipeline
Helicobacter pylori Infection Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Helicobacter pylori infection companies, including Phathom Pharmaceuticals, Redhill Biopharma, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvisé Pharmaceuticals, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Business Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Artificial Intelligence
Global Methane Hub Announces the Enteric Fermentation Research & Development Accelerator, a $200M Agricultural Methane Mitigation Funding Initiative
The Largest-Ever Globally Coordinated Funding Investment in Livestock Methane Mitigation Research Announced at the COP28 Business & Philanthropy Climate Forum
The public, private and philanthropic partnership includes Bezos Earth Fund, Quadrature Climate Fund, Gerstner Philanthropies, High Tide Foundation, Bill & Melinda Gates Foundation, The Zegar Family Foundation, Danone and more
DUBAI, UAE, Dec. 2, 2023 /PRNewswire/ — Today, at COP28, the Global Methane Hub (GMH) announced a more than $200 million funding initiative between public, private and philanthropic partners including the Bezos Earth Fund, Quadrature Climate Fund, Gerstner Philanthropies, High Tide Foundation, Bill & Melinda Gates Foundation, The Zegar Family Foundation, Danone, the Governments of Ireland, New Zealand and the United States, for research and development (R&D) technologies to meaningfully address and reduce methane emissions from livestock.
The Enteric Fermentation R&D Accelerator, or Accelerator, is the largest-ever, globally coordinated investment of breakthrough research tackling livestock methane emissions. The Global Methane Hub announced the intention to establish the Accelerator at COP27 as an AIM for Climate Innovation Sprint. The Accelerator will unite funders, guided by a science oversight committee, to invest in a globally coordinated research plan. This strategy aims to address gaps in current research and enhance existing efforts. The strategy includes work on exploring new and alternate livestock feed additives, tools to breed low-methane livestock, immunological studies for a methane vaccine, understanding the organisms in the rumen and their functions, and lowering the costs of measurement, essential to generate evidence for regulatory approval and validation of mitigation technologies.
About 40% of the world’s methane emissions come from agriculture, and 70% of that is due to enteric fermentation. This process happens in cows’ digestive systems when sugars are broken down into methane and released through belching. Unfortunately, current research on enteric fermentation is not extensive or coordinated enough to provide efficient and transformative solutions to significantly benefit farmers.
This is the latest milestone to mark the impact GMH is having on global methane reduction efforts since its founding in December 2021.
“The Accelerator is a prime example of the role philanthropy can play in driving substantive climate action and strategically aligning the key players working to solve the most pressing issue of our time,” said Hayden Montgomery, Agriculture Program Director at the Global Methane Hub. “With this effort to synchronize and consolidate public-good research on enteric methane, we aim to make multiple solutions to reduce enteric methane available quickly and provide proof of the efficacy of livestock mitigation technologies.”
“We know that cattle are responsible for most agricultural methane emissions. Promising technological and scientific solutions exist, but for too long, monetary and regulatory barriers have slowed progress and prevented critical research,” said Andy Jarvis, Director of Future of Food at the Bezos Earth Fund. “The Global Methane Hub’s Enteric Methane R&D Accelerator stands to change all of this, unlocking the resources needed to discover and develop low-cost solutions that will dramatically reduce methane emissions from livestock by 2030.”
“Through the Accelerator, we are poised to make a significant impact in driving innovation towards solutions to reduce enteric methane globally,” said Richard Lawrence, director and co-founder of High Tide Foundation. “I would like to thank Danone for stepping up as the first corporation committed to the Accelerator and I encourage others to do the same.”
“As a dairy company, curbing methane emissions is the fastest and most impactful way to slow down global warming,” said Olivier Verdelet, Vice-President Agriculture Cycle at Danone. “To do so, collaboration will be instrumental as we seek for new solutions, speed and sizable impacts. We are eager to collaborate with the Global Methane Hub and other partners to accelerate and test scalable innovations in the field. We believe this will help us build a sustainable, future-fit dairy category that is at the core of our mission to bring health through food to as many people as possible.”
Agricultural methane is projected to increase 40% by 2050. We would have to reduce emissions by 50% in order to meet the accords of the Paris Agreement to keep the global temperature rise to a maximum of 1.5 degrees Celsius. Reducing methane emissions from all sectors, including agriculture, is the fastest way to mitigate climate change.
Logo – https://mma.prnewswire.com/media/2291046/Global_Methane_Hub_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-methane-hub-announces-the-enteric-fermentation-research–development-accelerator-a-200m-agricultural-methane-mitigation-funding-initiative-302003837.html
Artificial Intelligence
Digital Printing for Tableware Market worth $452 million by 2029 – Exclusive Report by MarketsandMarkets™
CHICAGO, Dec. 1, 2023 /PRNewswire/ — The Digital Printing for Tableware market is projected to reach USD 452 million by 2029 from USD 326 million in 2024; it is expected to grow at a CAGR of 6.8% from 2024 to 2029 according to a new report by MarketsandMarkets™. Heightened interest in sustainable printing practices, escalating needs within the foodservice sector, swift advancements in digital printing technology, and the accelerated prototyping and assessment of novel designs within the tableware industry are poised to propel the expansion of the Digital Printing for Tableware market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=185181142
Browse in-depth TOC on “Digital Printing for Tableware Market”
140 – Tables60 – Figures240 – Pages
Digital Printing for Tableware Market Report Scope:
Report Coverage
Details
Market Revenue in 2024
$ 326 million
Estimated Value by 2029
$ 452 million
Growth Rate
Poised to grow at a CAGR of 6.8%
Market Size Available for
2020–2029
Forecast Period
2024–2029
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By Application, Ink type and Region
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Key Market Challenge
Compatibility with limited materials
Key Market Opportunities
Increasing demand from the in-plant market
Key Market Drivers
Rapid technological advancements in digital printers
This market exhibits a promising growth trajectory, buoyed by prospects like escalating demand from the in-plant market, substantial investment in digital printing-centric research and development endeavors, and the consequent decrease in per-unit printing costs facilitated by digital printers.
The Ceramic and porcelain application segment is expected to hold the largest market share of the digital printing for tableware market during the forecast period.
In 2023, the Ceramic and porcelain segment held the largest market share, and this pattern is expected to persist in the forecast period. Cutting edge ceramic digital printing technology for the tableware industry is expected to revolutionize the tableware industry during the forecast period. While digital printing for porcelain tableware combines precision and versatility allowing intricate designs to enable growth of the market. Digital printing for ceramic and porcelain tableware products involves the use of advanced printing technology to apply intricate and high-quality designs directly onto ceramic and porcelain surfaces. This modern printing method has become increasingly popular in the tableware industry due to its ability to offer customization, detailed graphics, and efficient production processes.
The UV Ink segment is expected to hold the largest market share of the digital printing for tableware market during the forecast period.
The use of UV ink in digital printing for the tableware industry is driven by its unique properties and advantages that cater to the specific requirements of decorating and customizing various tableware items, such as ceramics and porcelain. It offers rapid curing, color vibrancy, versatility in design, customization capabilities, durability, efficiency in production, and reduction in waste. Because of such advantages over other inks like ceramic ink, and solvent based ink, the UV ink type is expected to hold the largest market share.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=185181142
The North American region is expected to hold the largest market share during the forecast period.
During the forecast period, North America region is poised to experience the most significant growth in the digital printing for tableware market. The surge in consumer appetite for personalized tableware due to digital printing capabilities to deliver unique designs is expected to drive the market growth in the North American region. Also, presence of major companies such as Electronics for Imaging, Inc., Inkcups Now, Boston Industrial Solutions, Inc., and INX International Ink Co., in the North American region enables research and development activities in digital printing technologies benefitting the tableware industry owing to increase in the demand for customization of tableware products across the region.
Key Players Market
SACMI (Italy), Electronics for Imaging, Inc. (US), Inkcups Now (US), Mimaki Engineering Co., ltd. (Japan), Boston Industrial Solutions, Inc. (US), PROJECTA ENGINEERING S.R.L. (Italy), Engineered Printing Solutions (US), INX International Ink Co. (US), KERAjet (Spain), and Dip-Tech Digital Printing Technologies Ltd. (Israel) are key players in the digital printing for tableware companies.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=185181142
Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting
Related Reports:
Digital Printing Market Size, Share & Industry Growth Analysis Report by Ink (UV-cured, Aqueous, Solvent, Latex, and Dye Sublimation), Printheads (Inkjet and Laser), Substrate (Plastic Film or Foil, Release Liner, Glass, Textile, Paper, Ceramic), and Geography – Global Growth Driver and Industry Forecast to 2026
Digital Textile Printing Market by Printing Process (Roll to Roll, DTG), Ink Type (Sublimation, Pigment, Reactive, Acid), Application (Textile & Decor, Industrial, Soft Signage, Direct to Garment), and Geography – Global Forecast to 2023
Large Format Printer Market by Offering, Connectivity, Printing Material (Porous, Non-porous), Technology (Ink-based, Toner-based), Print Width, Ink Type, Application (Apparel & Textile, Signage & Advertising, Decor) and Region – Forecast to 2028
Production Printer Market by Type (Monochrome, Color), Technology (Inkjet, Toner), Production Method (Cut Sheet, Continuous Feed, Sheet Fed, and Web Based), Application and Geography – Global Trends & Forecast to 2022
3D Printing Market Size, Share & Industry Growth Analysis Report by Offering (Printer, Material, Software, Service), Process (Binder Jetting, Direct Energy Deposition, Material Extrusion, Material Jetting, Powder Bed Fusion), Application, Vertical, Technology and Region – Global Growth Driver and Industry Forecast to 2028
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact: Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Our Web Site: https://www.marketsandmarkets.com/Research Insight: https://www.marketsandmarkets.com/ResearchInsight/digital-printing-tableware-market.aspContent Source: https://www.marketsandmarkets.com/PressReleases/digital-printing-tableware.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/digital-printing-for-tableware-market-worth-452-million-by-2029—exclusive-report-by-marketsandmarkets-302002980.html
Leading global solutions provider showcases new product support for Oracle cloud backup and recovery operations and achieves AWS Level 1 MSSP Competency
MONTREAL, Dec. 1, 2023 /PRNewswire/ — Syntax Systems, a leading global technology solutions and services provider for cloud application implementation and management, announced Syntax CxLink Backup solution for Oracle databases at AWS re:Invent 2023. This is a strategic enhancement to its suite of solutions that now supports the Oracle Recovery Manager (RMAN). CxLink Backup addresses a critical need for enterprise customers running Oracle databases, including SAP customers, as Oracle Database underpins more than 60% of SAP ERP Central Component customer implementations and RMAN integration options are limited.
Enterprise teams managing multiple clouds and stores of data, each with their own routine for proper storage, now have access to a cutting-edge tool to simplify backup and recovery processes as well as disaster recovery strategies. With CxLink Backup, customers now have access to several impactful functions that Oracle Recovery Manager fulfills:
Spares users the complexity of managing backup file details because it’s a module that streamlines and automates backup and recovery.Supports various backup types like full, incremental, differential, and image copies.Enhances backup efficiency and minimizes size with features like compression, parallel processing, and multisection.Ensures data security and reliability through validation, encryption, and cataloging of backups, as well as the ability to rectify corruption or errors.Offers flexible data restoration, including options like flashback, point-in-time recovery, and incomplete recovery, which allows recovery to any specific moment.”In today’s fast-paced digital world, backups are critical for enterprise applications,” said Ricardo Casanovas Ortega, VP of Product Innovation at Syntax. “Many enterprise teams are managing these processes from disparate sources and tools. Our latest features for CxLink Backup, unify and automate recovery processes, giving users a powerful tool that enhances reliability while minimizing complexity.”
In addition to revealing new capabilities in its CxLink solution, Syntax also announced its achievement of the Amazon Web Services (AWS) Level 1 Managed Security Service Provider (MSSP) Competency and renewed its status in the AWS Managed Service Provider (MSP) Partner Program. These designations recognize and validate leading AWS Partner Network (APN) members that provide full lifecycle solutions to customers and who have met AWS’s requirements for a baseline of managed security services to protect and monitor essential AWS resources 24/7, known as Level 1 Managed Security Services.
“Syntax is very proud to now be part of the elite AWS Partners who have achieved the AWS Level 1 MSSP Competency,” said Christian Primeau, Global CEO of Syntax. “Our strategy is 3-pronged: operate-to-protect, monitor-to-respond and built-to-recover. We are focused on ensuring the integrity of applications running on AWS and the data they store and process. Achieving this AWS Competency designation is recognition of the work the Syntax team delivers and our growing relationship with AWS, which adds value across our entire portfolio.”
The Syntax portfolio offers a wide range of AWS solutions as an AWS Premier Tier Services Partner. Syntax previously achieved the AWS SAP Competency, AWS Oracle Competency, and AWS Migration Competency, and AWS MSP Partner designations and is a member of the AWS Well-Architected Partner Program.
About Syntax Syntax provides comprehensive technology solutions and trusted professional, advisory, and application management services to power businesses’ mission-critical applications in the cloud. With 50 years of experience and 800+ customers around the world, Syntax has deep expertise in implementing and managing multi-ERP deployments in secure private, public, hybrid, or multi-cloud environments. Syntax partners with SAP, Oracle, JD Edwards, AWS, Microsoft, and other global technology leaders to ensure customers’ applications are seamless, secure, and at the forefront of enterprise technology innovation. Learn more about Syntax at www.syntax.com.
Contact:Walker Sands for [email protected]
Logo – https://mma.prnewswire.com/media/2237121/4433147/Syntax_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/syntax-unveils-expanded-cxlink-backup-solution-at-aws-reinvent-2023-302002919.html
-
Artificial Intelligence6 days agoDental 3D Printing Market Revenue to Cross USD 16 billion by 2035, Registering at a CAGR 15.1% by 2035 | Roots Analysis
-
Artificial Intelligence7 days agoFovia Ai to Showcase Optimized AI Visualization at IAIP Exhibit, RSNA 2023
-
Artificial Intelligence6 days agoNew pothole initiative can’t make up for major job loss caused by Northern HS2 scrapping, says training expert Essential Site Skills (ESS)
-
Artificial Intelligence6 days agoUnited States Construction Industry Report 2023: Infrastructure and Commercial Investments are Expected to Lead Other Construction Sectors in H2 2023 and Q1 2024
-
Artificial Intelligence3 days agoNLP in Healthcare & Life Sciences Market worth $11.8 billion by 2028 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence2 days agoXevio Generates Quality Leads and Decreases Cost Per Lead (CPL) with MediaGo’s Smartbid Technology
-
Artificial Intelligence2 days ago
The World Internet of Things Convention 2023 Kicked off in China, the UN Secretary-General Sent the Message to the Convention
-
Artificial Intelligence2 days ago
Greater Than — 2023 Season of the FIA Smart Driving Challenge: Winner crowned after final in Dubai, UAE
